scholarly journals Detection and Prognostic Relevance of Circulating and Disseminated Tumour Cell in Dogs with Metastatic Mammary Carcinoma: A Pilot Study

Cancers ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 163 ◽  
Author(s):  
Laura Marconato ◽  
Antonella Facchinetti ◽  
Claudia Zanardello ◽  
Elisabetta Rossi ◽  
Riccardo Vidotto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Mammary Carcinoma ◽  
Peripheral Blood ◽  
Metastatic Breast ◽  
Negative Control ◽  
Tumour Cells ◽  
Breast Cancer Patients ◽  
Disseminated Tumour Cells ◽  
Speed Up

In human breast cancer, both circulating tumour cells (CTCs) in peripheral blood and disseminated tumour cells (DTCs) in the bone marrow are predictive of short survival and may be used as liquid biopsy to guide therapy. Herein we investigate, for the first time, the feasibility to quantify CTCs and DTCs in canine metastatic mammary carcinoma (MMC) with the automated CellSearch platform, which identifies tumour cells by immune-magnetic enrichment and fluorescent labelling. Using this approach before start of treatment, we could detect at least 1 CTC per 7.5 mL of peripheral blood in 12 out of 27 evaluable samples (44.4%) and at least 1 DTC per 1 mL of bone marrow in 11 out of 14 evaluable samples (78.6%). Conversely, we did not find any CTCs in the healthy, negative control dogs (n = 5) that we analysed in parallel. Interestingly, the levels of CTCs/DTCs and the prevalence of positive dogs closely resemble results obtained by CellSearch assay in metastatic breast cancer patients at diagnosis. Moreover, in the canine cohort, the presence of CTCs was significantly associated with poor outcome. These observations identify the first actionable marker in veterinarian oncology to guide treatment of canine MMC. Furthermore, our findings have important implications for human research, since it reinforce the value of canine MMC as model useful to speed up pharmacological studies with primary endpoint of overall survival, given the reduced life-span of the canine species.

1096 Molecular signatures of disseminated tumour cells in metastatic breast cancer patients

2009 ◽  
Vol 7 (2) ◽  
pp. 113-114
Author(s):  
L.O. Baumbusch ◽  
J.B. Geigl ◽  
S. Riethdorf ◽  
I.J. Schneider ◽  
R.M.R. Mathiesen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Tumour Cells ◽  
Molecular Signatures ◽  
Breast Cancer Patients ◽  
Disseminated Tumour Cells

scholarly journals ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients

2008 ◽  
Vol 10 (5) ◽  
Author(s):  
Tanja Fehm ◽  
Natalia Krawczyk ◽  
Erich-Franz Solomayer ◽  
Graziella Becker-Pergola ◽  
Silke Dürr-Störzer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Primary Breast Cancer ◽  
Tumour Cells ◽  
Breast Cancer Patients ◽  
Disseminated Tumour Cells

Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis

2021 ◽  
Vol 154 ◽  
pp. 128-137
Author(s):  
Andreas D. Hartkopf ◽  
Sara Y. Brucker ◽  
Florin-Andrei Taran ◽  
Nadia Harbeck ◽  
Alexandra von Au ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Pooled Analysis ◽  
Tumour Cells ◽  
Breast Cancer Patients ◽  
Disseminated Tumour Cells

Circulating Tumor Cells in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab and Chemotherapy

2009 ◽  
Vol 24 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Raquel A. Nunes ◽  
Xiaochun Li ◽  
Soonmo Peter Kang ◽  
Harold Burstein ◽  
Lisa Roberts ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Treatment Response ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Her 2

The detection of circulating tumor cells (CTCs) in peripheral blood may have important prognostic and predictive implications in breast cancer treatment. A limitation in this field has been the lack of a validated method of accurately measuring CTCs. While sensitivity has improved using RT-PCR, specificity remains a major challenge. The goal of this paper is to present a sensitive and specific methodology of detecting CTCs in women with HER-2-positive metastatic breast cancer, and to examine its role as a marker that tracks disease response during treatment with trastuzumab-containing regimens. The study included patients with HER-2-positive metastatic breast cancer enrolled on two different clinical protocols using a trastuzumab-containing regimen. Serial CTCs were measured at planned time points and clinical correlations were made. Immunomagnetic selection of circulating epithelial cells was used to address the specificity of tumor cell detection using cytokeratin 19 (CK19). In addition, the extracellular domain of the HER-2 protein (HER-2/ECD) was measured to determine if CTCs detected by CK19 accurately reflect tumor burden. The presence of CTCs at first restaging was associated with disease progression. We observed an association between CK19 and HER-2/ECD. The association of HER-2/ECD with clinical response followed a similar pattern to that seen with CK19. Finally, the absence of HER-2/ECD at best overall response and a change of HER-2/ECD from positive at baseline to negative at best overall response was associated with favorable treatment response. Our study supports the prognostic and predictive role of the detection of CTCs in treatment of HER-2-positive metastatic breast cancer patients. The association between CK19 and markers of disease burden is in line with the concept that CTCs may be a reliable measure of tumor cells in the peripheral blood of patients with metastatic breast cancer. The association of CTCs at first restaging with treatment failure indicates that CTCs may have a role as surrogate markers to monitor treatment response.

Sign in / Sign up

Export Citation Format

Share Document